Abstract:Spatiotemporally controlled cargo release is a key advantage of nanocarriers in anti-tumor therapy. Various external or internal stimuli-responsive nanomedicines have been reported for their ability to increase drug levels at the diseased site and enhance therapeutic efficacy through a triggered release mechanism. Redox-manipulating nanocarriers, by exploiting the redox imbalances in tumor tissues, can achieve precise drug release, enhancing therapeutic efficacy while minimizing damage to healthy cells. As a typical redox-sensitive bond, the disulfide bond is considered a promising tool for designing tumor-specific, stimulus-responsive drug delivery systems (DDS). The intracellular redox imbalance caused by tumor microenvironment (TME) regulation has emerged as an appealing therapeutic target for cancer treatment. Sustained glutathione (GSH) depletion in the TME by redox-manipulating nanocarriers can exacerbate oxidative stress through the exchange of disulfide-thiol bonds, thereby enhancing the efficacy of ROS-based cancer therapy. Intriguingly, GSH depletion is simultaneously associated with glutathione peroxidase 4 (GPX4) inhibition and dihydrolipoamide S-acetyltransferase (DLAT) oligomerization, triggering mechanisms such as ferroptosis and cuproptosis, which increase the sensitivity of tumor cells. Hence, in this review, we present a comprehensive summary of the advances in disulfide based redox-manipulating nanocarriers for anticancer drug delivery and provide an overview of some representative achievements for combinational therapy and theragnostic. The high concentration of GSH in the TME enables the engineering of redox-responsive nanocarriers for GSH-triggered on-demand drug delivery, which relies on the thiol-disulfide exchange reaction between GSH and disulfide-containing vehicles. Conversely, redox-manipulating nanocarriers can deplete GSH, thereby enhancing the efficacy of ROS-based treatment nanoplatforms. In brief, we summarize the up-to-date developments of the redox-manipulating nanocarriers for cancer therapy based on DDS and provide viewpoints for the establishment of more stringent anti-tumor nanoplatform.

Advances in redox-responsive drug delivery systems of tumor microenvironment

Progress in ROS Sensitive Nano-drug Delivery System

Redox-manipulating nanocarriers for anticancer drug delivery: a systematic review

Photo and Redox Dual Responsive Reversibly Cross-Linked Nanocarrier for Efficient Tumor-Targeted Drug Delivery

Redox-responsive Polymers for Drug Delivery: from Molecular Design to Applications

Redox-responsive Theranostic Nanoplatforms Based on Inorganic Nanomaterials

Modulating the cellular microenvironment with disulfide-containing nanoparticles as an auxiliary cancer treatment strategy

Redox Sensitive Nanoparticles with Disulfide Bond Linked Sheddable Shell for Intracellular Drug Delivery

Recent advances of redox-responsive nanoplatforms for tumor theranostics

Mechanisms, Challenges, and Therapeutic Applications

Nanomedicine-based Modulation of Redox Status for Cancer Therapy

Redox Stimuli-Responsive Hollow Mesoporous Silica Nanocarriers for Targeted Drug Delivery in Cancer Therapy

The progress of research on the application of redox nanomaterials in disease therapy

Redox‐Responsive Self‐Assembled Nanoparticles for Cancer Therapy

Reduction-Sensitive Nanosystems For Active Intracellular Drug Delivery

Redox-Responsive Mesoporous Silica Nanoparticles for Cancer Treatment: Recent Updates

Recent Progress in Anti-Tumor Nanodrugs Based on Tumor Microenvironment Redox Regulation

Redox-Responsive Supramolecular Micelles for Targeted Imaging and Drug Delivery to Tumor.

Hypoxia-activated Prodrugs and Redox-Responsive Nanocarriers

Controlled drug delivery with nanoassemblies of redox-responsive prodrug and polyprodrug amphiphiles

Redox-responsive molecular nanoreservoirs for controlled intracellular anticancer drug delivery based on magnetic nanoparticles.